AzTrials
AzTrials

Myocardial InfarctionMI-CBTNCT05128981

Internet-delivered Cognitive Behavioral Therapy Following Myocardial Infarction

A study testing MI-CBT in people with Myocardial Infarction and Cardiac Anxiety, run by Karolinska Institutet at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Myocardial infarction (MI) is one of the leading cause s of health loss globally, representing a large proportion of general disability. Anxiety and depression occur in 20-30 percent of patients following MI and have been identified as risk factors for recurrent adverse cardiac event. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Myocardial Infarction, Cardiac Anxiety, CBT
What is being tested?
MI-CBT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
1 siteSweden
Study dates
28 Oct 2021to 10 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ( - )MI ≥ 6 months before assessment ( - )Age 18-75 years endorsed cardiac anxiety that leads to significant distress or interferes with daily life (Cardiac Anxiety Questionnaire (CAQ); score ≥20) ( - ) On optimal medical treatment ( - )Able to read and write in Swedish.

Who cannot join

  • ( - ) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%) ( - ) significant valvular disease ( - ) planned coronary artery bypass surgery or other invasive therapy ( - ) other severe medical illness ( - )any medical restriction to physical exercise ( - )severe psychiatric disorder, severe depression, or risk of suicide ( - )alcohol dependency

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Karolinska Institutet

    Stockholm

Other trials in Sweden

About this study

Myocardial infarction (MI) is one of the leading cause s of health loss globally, representing a large proportion of general disability. Anxiety and depression occur in 20-30 percent of patients following MI and have been identified as risk factors for recurrent adverse cardiac event. The purpose of our this study is to develop and evaluate a disease specific cognitive behavioral therapy (C BT) protocol to reduce cardia anxiety, depression, increase physical inactivity and quality of life (Q oL) in patients following MI

Read the detailed description

The study will include 30 patients. The MI-specific CBT lasts for 8 weeks and is therapist guided and delivered via internet via a secure digital platform by licensed psychologists expertise in CBT for cardiac disease or final year psychologist under supervision. During treatment, the psychologists will have direct access to a cardiologist assigned to the project and treatments are conducted in close interdisciplinary collaboration to ensure patient safety

Being tested
MI-CBT
Medical subject headings
Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MI-CBTBehavioural

    Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention

Study groups in NCT05128981
Study groupRoleWhat they receive
MI-CBT via the InternetOtherThe MI-specific CBT will consist of 8 modules delivered via the Internet with home assignments that can be reviewed and reported in the research groups secure platform.
Receives: Behavioral: MI-CBT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 12-Item Short-Form Health Survey (SF-12)

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    Measured: Baseline

  2. 12-Item Short-Form Health Survey (SF-12)

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    Measured: 2 months from baseline

  3. 12-Item Short-Form Health Survey (SF-12)

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.

    Measured: 8 months from baseline

Secondary outcomes (34)
  1. Cardiac anxiety questionnaire

    Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.

    Measured: Baseline

  2. Cardiac anxiety questionnaire

    Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.

    Measured: 2 months from baseline

  3. Cardiac anxiety questionnaire

    Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.

    Measured: 8 months from baseline

  4. Body Sensation Questionnaire

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Measured: Baseline

  5. Body Sensation Questionnaire

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Measured: 2 months from baseline

  6. Body Sensation Questionnaire

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.

    Measured: 8 months from baseline

  7. Patient Health Questionnaire-9

    Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression

    Measured: Baseline

  8. Patient Health Questionnaire-9

    Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression

    Measured: 2 months from baseline

  9. Patient Health Questionnaire-9

    Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression

    Measured: 8 months from baseline

  10. Generalized Anxiety Disorder 7-item

    General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.

    Measured: Baseline

  11. Generalized Anxiety Disorder 7-item

    General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.

    Measured: 2 months from baseline

  12. Generalized Anxiety Disorder 7-item

    General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.

    Measured: 8 months from baseline

  13. The Godin Leisure-time Exercise

    Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.

    Measured: Baseline

  14. The Godin Leisure-time Exercise

    Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.

    Measured: 2 months from baseline

  15. The Godin Leisure-time Exercise

    Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.

    Measured: 8 months from baseline

  16. Tampas Scale for Kinesophobia-Heart version

    Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.

    Measured: Baseline

  17. Tampas Scale for Kinesophobia-Heart version

    Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.

    Measured: 2 months from baseline

  18. Tampas Scale for Kinesophobia-Heart version

    Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.

    Measured: 8 months from baseline

  19. Client satisfaction Questionnaire

    Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.

    Measured: Baseline

  20. Client satisfaction Questionnaire

    Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.

    Measured: 2 months from baseline

  21. Adverse events

    Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').

    Measured: 2 months from treatment

  22. Adverse events

    Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').

    Measured: 8 months from treatment

  23. Symptom Checklist (SCL)

    Measures frequency and severity of 16 cardiac-related symptoms. Scoring range from 0 to 64 for frequency with a greater score indicating more frequent symptoms, and from range from 0 to 48 for severity, with a greater score indicating more severe symptoms

    Measured: Baseline

  24. Symptom Checklist (SCL)

    Measures frequency and severity of 16 cardiac-related symptoms. Scoring range from 0 to 64 for frequency with a greater score indicating more frequent symptoms, and from range from 0 to 48 for severity, with a greater score indicating more severe symptoms

    Measured: 2 months from baseline

  25. Symptom Checklist (SCL)

    Measures frequency and severity of 16 cardiac-related symptoms. Scoring range from 0 to 64 for frequency with a greater score indicating more frequent symptoms, and from range from 0 to 48 for severity, with a greater score indicating more severe symptoms

    Measured: 8 months from baseline

  26. Perceived stress scale (4-item version)

    Stress reactivity. A greater score indicate more perceived stress.

    Measured: Baseline

  27. Perceived stress scale (4-item version)

    Stress reactivity. A greater score indicate more perceived stress.

    Measured: 2 months from Baseline

  28. Perceived stress scale (4-item version)

    Stress reactivity. A greater score indicate more perceived stress.

    Measured: 8 months from Baseline

  29. Insomnia Severity Index

    Measurement of sleep

    Measured: Baseline

  30. Insomnia Severity Index

    Measure of insomnia, score ranging from 0-20, with a higher score indicating more severe insomnia

    Measured: 2 months from Baseline

  31. Insomnia Severity Index

    Measure of insomnia, score ranging from 0-20, with a higher score indicating more severe insomnia

    Measured: 8 months from Baseline

  32. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

    Measure of post traumatic stress, score ranging from 0-80, with a higher score indicating more post traumatic stress.

    Measured: Baseline

  33. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

    Measure of post traumatic stress, score ranging from 0-80, with a higher score indicating more post traumatic stress.

    Measured: 2 months from Baseline

  34. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

    Measure of post traumatic stress, score ranging from 0-80, with a higher score indicating more post traumatic stress.

    Measured: 8 months from Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2021
  2. Study start28 Oct 2021
  3. Primary completion10 Dec 2022
  4. Study completion10 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05128981
Sponsor's protocol ID
CBT-MI
Acronym
MI-CBT
Status last verified
Jan 2023
First submitted
10 Nov 2021
Last updated
10 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing MI-CBT in people with Myocardial Infarction and Cardiac Anxiety, run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

12-Item Short-Form Health Survey (SF-12) (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in